Literature DB >> 3462331

Human melatonin in physiologic and diseased states: neural control of the rhythm.

G M Vaughan.   

Abstract

The human melatonin rhythm is endogenous with a surge of secretion entrained to the dark part of the cycle. Reports show consistent blunting or blockade of this nocturnal surge in the presence of sympathetic neurologic lesions and after administration of beta-adrenergic antagonists. However, there is remarkable resistance to elevation of daytime melatonin secretion by adrenergic agonists and by conditions of general sympathetic hyperactivity. Analysis of these and other reports together with results in lower animals allows insight into the control of the human melatonin rhythm. This rhythm is driven by a neural pathway to the pineal gland similar to that in animals and includes the sympathetic nervous system acting through a beta-adrenergic mechanism. Sympathetic control of the pineal is exerted independently of general sympathetic function, with sympathetic information partitioned separately for the pineal. The pineal is protected from humoral and exogenous adrenergic agents, in part by a nerve ending reuptake mechanism which has been demonstrated in rats and hamsters. Results in Syrian hamsters also suggest that sensitivity of the pineal to norepinephrine appears only at night. Melatonin production is an index, not of general sympathetic activity, but of the activity in a specific pathway and provides a stable humoral signal reflecting light/dark exposure. Observations of reduced melatonin values as a function of puberty, age, and depressive illness are not yet understood in the context of a unitary explanation of pineal function but indicate interesting frontiers in this field.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3462331

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  5 in total

1.  Marked enhancement by clorgyline of nocturnal and daytime melatonin release in rhesus monkeys.

Authors:  D L Murphy; N A Garrick; J L Hill; L Tamarkin
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

2.  The human pineal gland responds to stress-induced sympathetic activation in the second half of the dark phase: preliminary evidence.

Authors:  P Monteleone; M Maj; F Franza; R Fusco; D Kemali
Journal:  J Neural Transm Gen Sect       Date:  1993

3.  Influence of chronic beta-adrenoreceptor blocker treatment on melatonin secretion and sleep quality in patients with essential hypertension.

Authors:  T Rommel; L Demisch
Journal:  J Neural Transm Gen Sect       Date:  1994

4.  Low urinary 6-sulfatoxymelatonin levels in patients with severe congestive heart failure.

Authors:  Luis Girotti; Manuel Lago; Oscar Ianovsky; Marcelo V Elizari; Andrés Dini; Santiago Pérez Lloret; Liliana E Albornoz; Daniel P Cardinali
Journal:  Endocrine       Date:  2003-12       Impact factor: 3.633

Review 5.  Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection.

Authors:  Russel J Reiter; Ramaswamy Sharma; Fedor Simko; Alberto Dominguez-Rodriguez; Jan Tesarik; Richard L Neel; Andrzej T Slominski; Konrad Kleszczynski; Verna M Martin-Gimenez; Walter Manucha; Daniel P Cardinali
Journal:  Cell Mol Life Sci       Date:  2022-02-20       Impact factor: 9.207

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.